Dermata Therapeutics receives Nasdaq delisting notice for failing minimum stockholders' equity

Dermata Therapeutics, Inc.

Nasdaq notified Dermata on March 25, 2025, of non-compliance with $2.5M minimum stockholders' equity rule.
Company reported stockholders' equity of $1.6M as of Dec 31, 2024, below required threshold.
Dermata has 45 days, until May 9, 2025, to submit a plan; possible extension to Sept 21, 2025.
Securities continue trading on Nasdaq while company evaluates options to regain compliance.
If plan rejected or compliance not regained, delisting proceedings may commence; hearing available.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.